Several other brokerages have also weighed in on ANGO. Cantor Fitzgerald reissued a buy rating and set a $19.00 price objective on shares of AngioDynamics in a report on Tuesday, December 27th. Zacks Investment Research lowered AngioDynamics from a buy rating to a hold rating in a report on Tuesday, December 6th. Finally, KeyCorp set a $18.00 price objective on AngioDynamics and gave the company a buy rating in a report on Monday, September 12th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has a consensus rating of Hold and an average price target of $17.10.
Shares of AngioDynamics (NASDAQ:ANGO) traded down 1.95% during trading on Friday, reaching $17.11. The company’s stock had a trading volume of 207,792 shares. AngioDynamics has a 52-week low of $9.71 and a 52-week high of $17.64. The stock has a 50-day moving average of $16.77 and a 200-day moving average of $16.30. The stock’s market cap is $624.58 million.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Friday, January 6th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.03. AngioDynamics had a positive return on equity of 4.87% and a negative net margin of 7.91%. The business earned $89 million during the quarter. During the same period last year, the company posted $0.14 earnings per share. AngioDynamics’s revenue for the quarter was down .2% on a year-over-year basis. Analysts predict that AngioDynamics will post $0.67 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the company. BlackRock Investment Management LLC raised its position in AngioDynamics by 13.4% in the second quarter. BlackRock Investment Management LLC now owns 124,572 shares of the company’s stock worth $1,790,000 after buying an additional 14,686 shares during the last quarter. Principal Financial Group Inc. raised its position in AngioDynamics by 2.6% in the second quarter. Principal Financial Group Inc. now owns 186,924 shares of the company’s stock worth $2,686,000 after buying an additional 4,689 shares during the last quarter. Prudential Financial Inc. raised its position in AngioDynamics by 2.3% in the second quarter. Prudential Financial Inc. now owns 64,291 shares of the company’s stock worth $924,000 after buying an additional 1,420 shares during the last quarter. Dimensional Fund Advisors LP raised its position in AngioDynamics by 4.3% in the second quarter. Dimensional Fund Advisors LP now owns 2,968,384 shares of the company’s stock worth $42,655,000 after buying an additional 121,841 shares during the last quarter. Finally, Systematic Financial Management LP raised its position in AngioDynamics by 11.4% in the second quarter. Systematic Financial Management LP now owns 871,046 shares of the company’s stock worth $12,516,000 after buying an additional 88,967 shares during the last quarter. 75.72% of the stock is owned by hedge funds and other institutional investors.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
What are top analysts saying about AngioDynamics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AngioDynamics Inc. and related companies.